Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris

Jean-Baptiste Leclère, MD, Ludovic Fournel, MD, Harry Etienne, MD, Charbel Al Zreibi, MD, Ilaria Onorati, MD, Arnaud Roussel, MD, Yves Castier, MD, PhD, Emmanuel Martinod, MD, PhD, Françoise Le Pimpec-Barthes, MD, PhD, Marco Alifano, MD, PhD, Jalal Assouad, MD, PhD, and Pierre Mordant, MD, PhD, on behalf of the Thoracic Surgery Units of Paris Public Hospitals

Department of Vascular Surgery, Thoracic Surgery, and Lung Transplantation, Hôpital Bichat, Université de Paris, Paris, France; Department of Thoracic Surgery, Hôpital Cochin, Université de Paris, Paris, France; Department of Thoracic and Vascular Surgery, Hôpital Tenon, Sorbonne Université, Paris, France; Department of General Thoracic Surgery, Oncology, and Lung Transplantation, Hôpital Européen Georges-Pompidou, Université de Paris, Paris, France; and Department of Thoracic and Vascular Surgery, Hôpital Avicenne, Université Sorbonne Paris Nord, Paris, France

Background. The coronavirus disease 2019 (COVID-19) outbreak was officially declared in France on March 14, 2020. The objective of this study is to report the incidence and outcome of COVID-19 after surgical resection of non-small cell lung cancer in Paris Public Hospitals during the pandemic.

Methods. We retrospectively analyzed a prospective database including all patients who underwent non-small cell lung cancer resection between March 14, 2020, and May 11, 2020, in the 5 thoracic surgery units of Paris Public Hospitals. The primary endpoint was the occurrence of SARS-CoV-2 infection during the first 30 days after surgery.

Results. Study group included 115 patients (male 57%, age 64.6 ± 10.7 years, adenocarcinoma 66%, cT1 62%, cN0 82%). During the first month after surgery, 6 patients (5%) were diagnosed with COVID-19. As compared with COVID-negative patients, COVID-positive patients were more likely to be operated on during the first month of the pandemic (100% vs 54%, P = .03) and to be on corticosteroids preoperatively (33% vs 4%, P = .03). Postoperative COVID-19 was associated with an increased rate of readmission (50% vs 5%, P = .004), but no difference in 30-day morbidity (for the study group: grade 2, 24%; grade 3, 7%; grade 4, 1%) or mortality (n = 1 COVID-negative patient, 0.9%). Immediate oncologic outcomes did not differ significantly between groups (R0 resection 99%, nodal upstaging 14%, adjuvant chemotherapy 29%).

Conclusions. During the COVID-19 pandemic, surgical treatment of non-small cell lung cancer was associated with a rate of postoperative COVID-19 of 5% with a significant impact on readmissions but not on other outcomes studied.

(Ann Thorac Surg 2021;111:1682-8) © 2021 by The Society of Thoracic Surgeons

After an early phase of slow virus spread, the coronavirus disease 2019 (COVID-19) outbreak was officially declared in France on March 14, 2020, and a national lockdown was established on March 16, 2020. By the end of March, there were 52,128 confirmed COVID-19 cases in France, including 22,757 patients requiring hospitalization, 5,565 requiring intensive care, and a death toll of 3,523.1 After the eastern region, Paris and its vicinity quickly appeared to be the second epicenter of the disease in France, stretching the health care system with a huge number of patients, forcing Paris hospitals to double their intensive care unit capacity, to transfer intensive care unit patients to distant regional hospitals, and to postpone non-urgent surgical procedures.1

Whether surgical resection of cancer can be considered an urgent or semiurgent procedure is questionable. Specifically, there is no consensus on the impact of delay in the surgical management of non-small cell lung cancer (NSCLC). Yang and associates2 analyzed the US National Cancer Database and found that an interval longer than 6 to 12 weeks between diagnosis of early-stage NSCLC and surgery was associated with worse survival. General guidelines from the National Comprehensive Cancer Network state that treatment delays should be avoided,3 and those from the European Society for Medical Oncology4 and the American College of Chest Physicians5 do not mention any time limit to initiate surgical intervention. Conversely, European Nordic countries have organized integrated cancer pathways to ensure a rapid and well-coordinated course of treatment, and low-
risk patients with early-stage NSCLC are required to receive surgery within 14 calendar days after completion of diagnostic workup.6

At the beginning of the COVID-19 pandemic, there was no specific guideline to address the surgical management of NSCLC in this particular period. The ethical guidelines driving the care of COVID-19 patients were already widely discussed, and included maximizing benefits, treating equally, promoting and rewarding instrumental value, and giving priority to the worst off.7 Even if the management of non-COVID-19 patients was not discussed by then, we considered that the value of maximizing benefits during a pandemic should be applied equally to all patients, whatever their underlying disease. Accordingly, the French High Counsel of Public Health (Haut Conseil de Santé Publique) published guidelines on the care of cancer patients during a pandemic, and advised prioritizing cancer care to patients with a high likelihood of cure.8 In this context, we organized a specific COVID-free surgical path to preserve the surgical resections of NSCLC planned with curative intent in low-risk patients and patients whose tumor was to be operated rapidly. The objective of this study is to report the incidence and outcome of COVID-19 after surgical resection of NSCLC in Paris Public Hospitals during the COVID-19 pandemic.

Patients and Methods

Study Design

We set a retrospective study of a prospectively maintained multicentric administrative database, including all patients who underwent surgical treatment of NSCLC in Paris, France, from the official announcement of the COVID-19 outbreak until the end of the national lockdown. Inclusion criteria were patients with NSCLC undergoing surgery with curative intent from March 14, 2020, to May 11, 2020, in the thoracic surgery departments of Avicenne Hospital, Bichat Hospital, Cochin Hospital, Georges-Pompidou European Hospital, and Tenon Hospital, all part of Assistance Publique – Hôpitaux de Paris, a network of 39 public hospitals totaling 20,000 beds in Paris and its vicinity. We reviewed patient characteristics, surgical procedures, short-term outcomes, pathology results, and occurrence of postoperative COVID-19. The study was split in 2 time periods. The early time period was set from March 14 to April 14, and corresponded to an increase in the number of hospitalized COVID-19 cases in our institution, followed by a plateau of around 4,500 patients or 22% of Assistance Publique – Hôpitaux de Paris capacity. The late time period was set from April 15 to May 11, and corresponded to a progressive decline in the number of hospitalized COVID-19 patients.

Endpoints

The primary endpoint was the incidence and prognosis of polymerase chain reaction (PCR)-proven postoperative COVID-19 during the first 30 days after surgery (30-day COVID-19). Secondary endpoints included the occurrence of any complication according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 during the first 30 days after surgery (30-day morbidity), the occurrence of death of any cause during the first 30 days after surgery (30-day mortality), the proportion of patients with complete resection on the surgical specimen (R0 resection), and the proportion of patients with suspected COVID-19 on the pathologic examination of the surgical specimen (day 0 COVID-19).

Ethical Aspects

All patients signed an informed consent to authorize prospective data collection and retrospective data analysis. The database was declared to the National Board for Informatics and Freedom (Commission Nationale Informatique et Liberté authorization #2217817) and to the National Institute for Health Data (Institut National des Données de Santé authorization #MR1313290420). The study was approved by the ethics committee of the French Society of Thoracic and Cardiovascular Surgery (Société Française de Chirurgie Thoracique et Cardiovasculaire authorization #CERC-SFCTCV-2020-05-06-07-MOPI).

Preoperative Management

All cases were discussed preoperatively and postoperatively during a multidisciplinary meeting including a pulmonologist, an oncologist, a thoracic surgeon, a radiation therapist, a radiologist, and a pathologist to confirm the surgical management of NSCLC and its timing in case of multimodal strategy. The risk of postoperative mortality was estimated using the Thoraco-score.7 Thoracic surgery units were organized as COVID-free units where every suspected COVID-19 case was immediately transferred to a medical unit dedicated to COVID-19 patients. For surgical candidates, screening of COVID-19 was performed the day before surgery. In the early time period, screening was based on a careful interview and a complete clinical examination. In the late time period, screening was based on careful interview, complete clinical examination, and systematic SARS-CoV-2 PCR on nasopharyngeal swab. Preoperative low-dose chest computed tomography (CT) was rarely performed. The surgery was postponed if the patient was determined to have symptoms, physical examination or CT findings consistent with COVID-19 infection, or a positive SARS-CoV-2 PCR.

Surgery

When the surgery was confirmed, patients were equipped with a surgical mask and transferred to the operating room. The anesthesiology team wore FFP2 masks during intubation, bronchoscopy, and endotracheal tube manipulation to ensure selective ventilation. The surgical team wore surgical masks during the procedure. The surgical procedure was performed according to multidisciplinary meeting decision and surgeon’s preference, with a closure of the bronchial stump using double-sided endostapler to avoid bronchial opening whenever
feasible. Patients wore a surgical mask during their transfer to the recovery room, in the recovery room, and during their transfer back to their room in the thoracic surgery unit. Postoperative chest CT and SARS-CoV-2 PCR were performed only if a postoperative COVID-19 infection was suspected, during initial hospitalization, after discharge, or upon readmission. In case of postoperative COVID-19, the severity of lung involvement was estimated on chest CT.10

Statistical Analysis
Categorical variables were presented as numbers and proportions and compared with χ² or Fisher’s exact test when appropriate. Continuous variables with normal distribution were reported as mean ± SD and compared using Student’s t test or Welch 2-sample t test when appropriate. Continuous variables with non-normal distribution were reported as median (interquartile range) and compared using the Mann-Whitney test. The 30-day follow-up was complete for all patients. All data analyses were conducted with 2-sided tests, without adjustment for multiple comparisons. A P value less than .05 was considered significant. Follow-up updates and final statistical analysis were performed on June 27, 2020. Statistical analyses were conducted using R (The R Statistical Software, R Foundation, Vienna, Austria).

Results

Patient Characteristics
From March 14, 2020, to May 11, 2020, 115 patients were admitted in the 5 thoracic surgery departments of Paris Public Hospitals for surgical treatment of NSCLC. Demographic and clinical features are developed in Table 1.

Preoperative Workup
Preoperative tumor assessment is presented in Table 2. Average tumor size was 28.4 ± 15.7 mm (range, 5-90 mm). Eight patients (7%) underwent induction chemotherapy. In 1 patient, a recent CT scan retrospectively showed additional alveolar opacities around a 4-cm tumor.

Surgical Treatment
Details of surgical management are developed in Table 3. One patient was operated in emergency conditions. Three patients (3%) underwent delayed surgery because of the pandemic context. One patient died 6 days after a right pneumonectomy due to bacterial pneumonia and pulmonary embolism with negative COVID-19 testing.

Oncological Outcome
Immediate oncological outcomes are presented in Table 4. One patient (1%) had R1 resection. Postoperative multidisciplinary meeting decision was available in 77

| Variable                        | Study Group (N = 115) | No Postoperative COVID-19 (n = 109) | Postoperative COVID-19 (n = 6) | P Value |
|---------------------------------|-----------------------|-----------------------------------|--------------------------------|---------|
| Demographics                    |                        |                                   |                                |         |
| Age, y                          | 64.6 ± 10.7           | 64.5 ± 10.9                       | 66.0 ± 4.4                     | .43     |
| Male sex                        | 65 (57)               | 61 (56)                           | 4 (67)                         | .70     |
| BMI, kg/m²                      | 24.4 ± 8.0            | 24.3 ± 8.1                        | 27.6 ± 5.3                     | .20     |
| Smoking history                 | 99 (86)               | 94 (86)                           | 5 (83)                         | .99     |
| Active smoking                  | 33 (29)               | 32 (30)                           | 1 (17)                         | .67     |
| Extrapulmonary diseases         |                        |                                   |                                |         |
| Diabetes                        | 15 (13)               | 13 (12)                           | 2 (33)                         | .17     |
| Kidney failure                  | 4 (3)                 | 4 (4)                             | 0                              | .99     |
| Ischemic heart disease          | 18 (16)               | 16 (15)                           | 2 (33)                         | .24     |
| Hypertension                    | 50 (43)               | 46 (42)                           | 4 (67)                         | .40     |
| ACE inhibitor                   | 26 (23)               | 24 (22)                           | 2 (33)                         | .62     |
| History of organ transplantation| 2 (2)                 | 2 (3)                             | 0                              | .99     |
| Corticosteroid therapy          | 6 (5)                 | 4 (4)                             | 2 (33)                         | .03     |
| Immunosuppressive therapy       | 7 (6)                 | 6 (6)                             | 1 (17)                         | .32     |
| Respiratory function            |                        |                                   |                                |         |
| History of thoracic surgery     | 13 (11)               | 11 (10)                           | 2 (33)                         | .14     |
| COPD                            | 32 (28)               | 30 (28)                           | 2 (33)                         | .67     |
| FEV1, %th                       | 86.5 ± 18.6           | 87.1 ± 18.2                       | 76.2 ± 24.9                    | .34     |
| TLC, %th                        | 104.0 ± 17.7          | 103.8 ± 17.7                      | 107.3 ± 20.2                   | .76     |
| DLCO, %th                       | 66.5 ± 17.2           | 65.9 ± 17.0                       | 74.4 ± 21.3                    | .43     |
| Thoracoscore, %                 | 2.0 ± 1.4             | 2.0 ± 1.4                         | 2.77 ± 1.49                    | .26     |

Values are presented as mean ± SD or n (%).

ACE, angiotensin-converting enzyme; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiration volume in 1 s; TLC, total lung capacity; %th, % of predicted values.
patients, among which adjuvant chemotherapy was decided in 22 (29%), chemoradiotherapy in 4 (5%), and targeted therapy in 1 (1%).

Postoperative COVID-19
No sign of SARS-CoV-2 infection in the lung parenchyma was noticed on surgical specimen (day 0 COVID-19). Six patients (5%) were diagnosed with COVID-19 during the first postoperative month (30-day COVID-19). All of them had surgery during the first month of the study (early time period). Their management is detailed in Tables 5 and 6.

The occurrence of postoperative COVID-19 was associated with a higher rate of readmission (50% vs 5%, \(P = .004\)), but not with longer initial hospital length of stay, increased 30-day morbidity, or increased 30-day mortality. At the time of analysis, all patients with postoperative COVID-19 returned home without oxygen support. In univariate analysis of preoperative risk factors, earlier vs late time-period (\(P = .03\)) and preoperative corticosteroid therapy (\(P = .03\)) were significantly associated with the occurrence of a postoperative COVID-19.

Comment
While monitoring the occurrence of postoperative SARS-CoV-2 infection after surgical treatment of NSCLC during the COVID-19 pandemic in Paris, France, we found a frequency of 5% with an impact on readmissions but no impact on postoperative morbidity or mortality.

**Table 2. Tumor Characteristics**

| Variable              | No Postoperative COVID-19 (n = 115) | Postoperative COVID-19 (n = 6) | \(P\) Value |
|-----------------------|------------------------------------|-------------------------------|------------|
| Tumor size, mm        | 28.4 ± 15.7                        | 28.3 ± 15.8                   | 29.8 ± 15.7 | .83        |
| cT1                   | 69 (62)                            | 66 (62)                       | 3 (50)     | .37        |
| cT2                   | 27 (23)                            | 26 (25)                       | 1 (17)     | .37        |
| cT3                   | 12 (11)                            | 10 (9)                        | 2 (33)     | .37        |
| cT4                   | 4 (4)                              | 4 (4)                         | 0          | .37        |
| Nodal status          |                                    |                               |            |            |
| cN0                   | 94 (82)                            | 89 (82)                       | 5 (83)     | .69        |
| cN1                   | 10 (9)                             | 10 (9)                        | 0          | .69        |
| cN2                   | 10 (9)                             | 9 (9)                         | 1 (17)     | .69        |
| Metastatic status     |                                    |                               |            | .99        |
| cM0                   | 108 (94)                           | 102 (94)                      | 6 (100)    | .99        |
| cM1a                  | 2 (2)                              | 2 (2)                         | 0          | .99        |
| cM1b                  | 4 (3)                              | 4 (4)                         | 0          | .99        |
| cM1c                  | 0                                 | 0                             | 0          | .99        |
| Histology             |                                    |                               |            |            |
| Preoperative histology| 49 (43)                            | 45 (41)                       | 4 (67)     | .54        |
| Induction chemotherapy | 8 (7)                              | 7 (6)                         | 1 (17)     | .34        |

Values are presented as mean ± SD or n (%).

**Table 3. Surgical Management**

| Variable              | No Postoperative COVID-19 (n = 115) | Postoperative COVID-19 (n = 6) | \(P\) Value |
|-----------------------|------------------------------------|-------------------------------|------------|
| Time period           | 65 early/50 late                   | 59 early/50 late              | 6 early/0 late | .03   |
| Approach              | Open surgery                       | VATS                          | RATS       | .01   |
| Segmentectomy         | 19 (17)                            | 19 (17)                       | 0          | .01   |
| Lobectomy             | 86 (74)                            | 81 (74)                       | 5 (83)     | .01   |
| Pneumonecctomy        | 7 (6)                              | 7 (6)                         | 0          | .01   |
| Type of complications |                                    |                               |            | .01   |
| Prolonged air leak    | 18 (16)                            | 17 (16)                       | 1 (17)     | .01   |
| Bacteria pneumonia    | 11 (10)                            | 11 (10)                       | 0          | .01   |
| Atrial fibrillation   | 5 (4)                              | 5 (5)                         | 0          | .01   |
| DVT/PE                | 2 (2)                              | 1 (1)                         | 1 (17)     | .01   |
| Inferior laryngeal nerve palsy | 1 (1) | 0 | 1 (17) | .01 |

**NCI CTCAE 5.0 Classification**

| Grade | No Postoperative COVID-19 (n = 115) | Postoperative COVID-19 (n = 6) | \(P\) Value |
|-------|------------------------------------|-------------------------------|------------|
| Grade 1 | 21 (18)                            | 19 (17)                       | 2 (33)     | .30   |
| Grade 2 | 28 (24)                            | 27 (25)                       | 1 (17)     | .99   |
| Grade 3 | 8 (7)                              | 4 (4)                         | 4 (67)     | .001  |
| Grade 4 | 1 (1)                              | 1 (1)                         | 0          | .99   |
| Grade 5 | 1 (1)                              | 1 (1)                         | 0          | .99   |
| Chest tube duration, d | 3 (2-5)                            | 3 (2-5)                       | 3 (3-5)    | .53   |
| Hospital length of stay, d | 7 (5-11)                           | 7 (5-10)                      | 5 (4-9)    | .73   |
| Readmission | 8 (7)                             | 5 (5)                         | 3 (50)     | .004  |

Values are presented as median (interquartile range) or n (%).

DVT/PE, deep venous thrombosis/pulmonary embolism; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; RATS, robot assisted thoracic surgery; VATS, video assisted thoracic surgery.

When the COVID-19 outbreak was declared in France, there were no specific guidelines dedicated to the surgical management of patients with NSCLC. Early French guidelines recommended discussion in a multidisciplinary setting and on a case-by-case basis, and suggested postponing non-urgent surgical management of NSCLC patients or considering alternative treatments. Since then, different guidelines recommended to preemptively postpone surgery for stage I tumors up to 2 cm or 3 cm.
whereas an expert thoracic oncology multidisciplinary consensus opinion recommended considering non-surgical treatment for locally advanced NSCLC. Conversely, the British Thoracic Society and the European Society of Medical Oncology advised following the standard of care until limitations of surgical resources actually arise. We reached the same conclusion and decided to preserve the surgical resections of NSCLC until resources are effectively limited.

To minimize the risk of nosocomial COVID-19, all visits were prohibited and wearing surgical masks by all caregivers was mandatory after March 18, 2020 (ie, 4 days after the beginning of our study). No systematic screening of caregivers or asymptomatic patients was possible at this time. For suspected or confirmed cases of COVID-19, infection prevention and control strategies included contact, airborne, and droplet precautions for health care staff. Personal protective equipment consisted of gowns, gloves, eye protection, and either medical masks for standard care or FFP2 masks during airway aerosol-generating procedures. Despite some tensions on the supply chain, no limitations on the use of personal protective equipment were reported in our institution, and no competition in the allocation of personal protective equipment were noticed between COVID-19 and non-COVID-19 units.

Given the natural history of the disease and the timing of postoperative diagnosis, half of the patients with postoperative COVID-19 reported here might have had the virus before surgery or have been infected in the hospital. Modeling analyses of the burden of COVID-19 in France estimated that by May 11, 2020, 4.4% of the population might have been infected, and possibly up to 9.9% in the Ile-de-France region, which includes Paris. The frequency of postoperative COVID-19 reported in our study was therefore similar to the incidence of SARS-CoV-2 infection expected in the community setting of the surrounding area. Interestingly, our study encompasses the French lockdown, which was associated with a significant drop in the virus effective reproduction number (R) down to 0.6. It seems therefore unlikely that silently infected thoracic surgery patients could have spread the virus after discharge.

Cancer therapies can lead to prolonged immunosuppressive states that may affect the incidence of severe infection-related morbidities and mortality. A recent study from New York identified 69 consecutive outpatients with lung cancer who were diagnosed with COVID-19, including 42 patients (62%) requiring hospitalization and 16 patients (24%) who died. The role of treatments in this adverse prognosis is still to be established. Studying 28 cancer patients with COVID-19, Zhang and colleagues found that a last antitumor treatment within 14 days

| Table 4. Oncologic Outcome | Study Group (N = 115) | No Postoperative COVID-19 (n = 109) | Postoperative COVID-19 (n = 6) | P Value |
|----------------------------|----------------------|-----------------------------------|-------------------------------|--------|
| Variable                   |                      |                                   |                               |        |
| Histology                  |                      |                                   |                               |        |
| Adenocarcinoma             | 75 (66)              | 71 (66)                           | 4 (67)                        | .85    |
| Squamous cell carcinoma    | 23 (20)              | 21 (19)                           | 2 (33)                        | .41    |
| Large cell carcinoma       | 2 (2)                | 2 (2)                             | 0                             | .99    |
| Carcinoid tumor            | 8 (7)                | 8 (7)                             | 0                             |        |
| Other                      | 6 (5)                | 6 (6)                             | 0                             |        |
| Tumor size, mm             | 25.9 ± 14.3          | 25.6 ± 14.1                       | 28.7 ± 18.5                   | .66    |
| pT1                        | 59 (52)              | 57 (52)                           | 2 (33)                        | .45    |
| pT2                        | 36 (31)              | 34 (31)                           | 2 (33)                        |        |
| pT3                        | 15 (13)              | 13 (12)                           | 2 (33)                        |        |
| pT4                        | 5 (4)                | 5 (5)                             | 0                             |        |
| Nodal status               |                      |                                   |                               |        |
| pN0                        | 89 (77)              | 85 (78)                           | 4 (67)                        |        |
| pN1                        | 12 (11)              | 11 (10)                           | 1 (17)                        |        |
| pN2                        | 14 (12)              | 13 (12)                           | 1 (17)                        |        |
| Resection margin           |                      |                                   |                               |        |
| R0                         | 114 (99)             | 108 (99)                          | 6 (100)                       |        |
| R1                         | 1 (1)                | 1 (1)                             | 0                             |        |
| Postoperative MDM decision| (n = 77)             | (n = 71)                          | (n = 6)                       | .58    |
| No adjuvant treatment      | 50/77 (65)           | 47/71 (66)                        | 3/6 (50)                      |        |
| Adjuvant chemotherapy      | 22/77 (29)           | 19/71 (27)                        | 3/6 (50)                      |        |
| Adjuvant chemoradiation    | 4/77 (5)             | 4/71 (6)                          | 0                             |        |
| Adjuvant targeted therapy  | 1/77 (1)             | 1/71 (1)                          | 0                             |        |

Values are presented as mean ± SD, n (%), or n/N (%).

MDM, multidisciplinary meeting.
significantly increased the risk of developing severe events. Focusing on NSCLC surgery, a small retrospective series from China reported postoperative COVID-19 to be associated with mortality rate up to 42%.22 In our study, the occurrence of postoperative COVID-19 was not associated with any increase in the overall morbidity or mortality after surgery for NSCLC, and most readmissions were indeed preemptive in the postoperative setting.

Study limitations include the absence of systematic screening of asymptomatic patients both preoperatively and postoperatively. We also regret the lack of control group from the pre-COVID-19 era, but the outcomes after surgical resection of NSCLC reported here are in line with the outcomes reported in pre-COVID-19 publications from the French national database Epi-thor.23 Our study is also limited by its retrospective analysis, small groups, and absence of adjustment for multiple comparisons. These limitations can be counterbalanced by the prospective data collection, exhaustiveness of data on patients undergoing NSCLC surgery in Paris Public Hospitals during the first 2 months of the COVID-19 pandemic, and complete 30-day follow-up.

We can conclude that the surgical treatment of NSCLC during the first 2 months of the COVID-19 pandemic in Paris, France, was associated with a rate of postoperative COVID-19 of 5%, similar to that expected in the community setting. Postoperative COVID-19 was associated with higher rate of readmission, but with no adverse

| Table 5. Characteristics of Postoperative COVID-19 Patients (n = 6) |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Patient | Sex, Age | Tobacco Use | Medical History | Preoperative FEV1 | subtype, cTNM | Surgery, Approach, Date (dd/mm) | pTNM, Resection | MDM Decision |
| 1 | F 58 y | Weaned | Arthritis/CS | 81% | Adk cT3N0M0 | LUL Lobectomy RATS 14/03 | pT2bN0M0 R0 | Adjuvant CTX postponed due to COVID |
| 2 | M 66 y | Weaned | IHD/AEC Arthritis/IS + CS | 77% | SCC cT1cN0M0 | RLL Wedge VATS 16/03 | pT1bN0M0 R0 | No adjuvant treatment |
| 3 | M 66 y | Active | Diabetes/ACE | 84% | Adk cT1bN0M0 | LUL Lobectomy RATS 16/03 | pT2N1M0 R0 | Adjuvant CTX performed |
| 4 | F 69 y | No | No | 114% | Adk cT1bN0M0 | RUL Lobectomy VATS 23/03 | pT1bN0M0 R0 | No adjuvant treatment |
| 5 | M 70 y | Weaned | Diabetes IHD COPD | 39% | Adk cT3N2M0 Induction CTX | RUL lobectomy + SVC Open 30/03 | pT3N2M0 R0 | No adjuvant treatment |
| 6 | M 68 y | Weaned | COPD | 62% | SCC cT2bN0M0 | LUL Lobectomy RATS 02/04 | pT3N0M0 R0 | Adjuvant CTX cancelled due to COVID |

ACE, angiotensin converting enzyme inhibitor; Adk, adenocarcinoma; COPD, chronic obstructive pulmonary disease; CS, corticosteroids; CTX, chemotherapy; F, female; IHD, ischemic heart disease; IS, immunosuppression; LUL, left upper lobe; M, male; MDM, multidisciplinary meeting; RATS, robot assisted thoracic surgery; RLL, right lower lobe; RUL, right upper lobe; SCC, squamous cell carcinoma; SVC, superior vena cava; VATS, video assisted thoracic surgery.

| Table 6. Postoperative Course of Postoperative COVID-19 Patients (n = 6) |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Patient | Surgery to Spt (d) | Surgery to PCR (d) | Surgery to Chest CT (d) | Chest CT Severity (%) | Patient Management | Respiratory Support | COVID-19 Treatment | Follow-up |
| 1 | 2 | 3 | 6 | <10% | Same hospitalization, total 11 days | No | None | 92 d alive at home early recurrence |
| 2 | 17 | 17 | 18 | <10% | Readmission, total 13 days | No | Amoxicillin clavulanate | 94 d alive at home |
| 3 | 3 | 3 | Not performed | Not performed | Outpatient | No | Amoxicillin clavulanate | 94 d alive at home |
| 4 | 8 | 16 | 16 | 25% | Readmission, total 8 days | No | H+A+C | 86 d alive at home |
| 5 | No symptom | 30 | Not performed | Not performed | Readmission, total 7 days | No | None | 45 d alive at home |
| 6 | 4 | 4 | 6 | <10% | Same hospitalization, total 24 days | No | Amoxicillin clavulanate | 77 d alive at home |

CT, computed tomography; H+A+C, hydroxychloroquine + azithromycin + corticosteroids; PCR, polymerase chain reaction test; Spt, symptoms.
impact on postoperative morbidity, mortality, or immediate oncologic outcomes. Further studies are needed to clarify the risk factors, patients-reported outcomes, and long-term consequences of postoperative COVID-19.

References

1. French Public Health Agency (Santé Publique France). COVID-19 Dashboard. Available at: https://dashboard.covid19.data.gouv.fr/vue-d-ensemble?location=FRA. Accessed August 18, 2020.
2. Yang CJ, Wang H, Kumar A, et al. Impact of timing of lobectomy on survival for clinical stage IA lung squamous cell carcinoma. Chest. 2017;152:1239-1250.
3. Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015;13:515-524.
4. Vansteenkiste J, Crino L, Dooms C, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25:1462-1474.
5. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-e313S.
6. Christensen NL, Jekunen A, Heinonen S, Dalton SO, Rasmussen TR. Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison. Acta Oncol. 2017;56:943-948.
7. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382:2049-2055.
8. French High Council for Public Health (Haut Conseil de la santé publique, HCSP). COVID-19 Guidelines for Cancer Patients. Available at: https://www.hcsp.fr/Explore/cgi/Telecharger?NomFichier=hcspx20200314_apprilpelpedcclpdrds.pdf. Accessed August 18, 2020.
9. Falcoz PE, Conti M, Brouchet L, et al. The thoracic surgery scoring system (Thorascore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. J Thorac Cardiovasc Surg. 2007;133:325-332.
10. Revel MP, Parkar AF, Prosh H, et al. COVID-19 patients and the radiology department—advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). Eur Radiol. 2020;30:4903-4909.

11. Girard N, Grellier L, Zalcman G, et al. Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. Respir Med Res. 2020;78:100769.
12. American College of Surgeons. COVID-19 Guidelines for Triage of Thoracic Patients. Available at: https://www.facs.org/covid-19/clinical-guidance/ elective-case/thoracic-cancer. Accessed August 18, 2020.
13. Li X, Liu M, Zhao Q, et al. Preliminary recommendations for lung surgery during COVID-19 epidemic period. Thorac Cancer. 2020;11:1372-1374.
14. Kumar S, Chmura S, Robinson C, et al. Alternative multi-disciplinary management options for locally advanced NSCLC during the coronavirus disease 2019 global pandemic. J Thorac Oncol. 2020;15:1119-1136.
15. Dingemans AC, Soo RA, Jazieh AR, et al. Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic. J Thorac Oncol. 2020;15:1119-1136.
16. British Thoracic Society. COVID-19 Guidelines for NSCLC patients. Available at: https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/lung-cancer-pathway-guidance-covid-19/. Accessed August 18, 2020.
17. European Society of Medical Oncology. ESMO management and treatment adapted recommendations in the COVID-19 era: lung cancer. Available at: www.esmo.org. Accessed August 18, 2020.
18. Bouadma L, Lescure FX, Lucet JC, Yazdanpanah Y, Timsit JF. Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists. Intensive Care Med. 2020;46:579-582.
19. Salje H, Tran Kiem C, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369:208-211.
20. Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 2020;10:1121-1128.
21. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31:894-901.
22. Peng S, Huang L, Zhao B, et al. Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis. J Thorac Cardiovasc Surg. 2020;160:585-592.e2.
23. Pagès PB, Delpy JP, Orsini B, et al. Propensity score analysis comparing videothoracoscopic lobectomy with thoracotomy: a French nationwide study. Ann Thorac Surg. 2016;101:1370-1378.